Washington, May 23 (ANI): A novel herb-based therapeutic called Zyflamend has been found to be linked with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer in its phase I clinical trial.
The trial was led by researcher from the Center for Holistic Urology at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia.
Writing in the Journal of the Society for Integrative Oncology, the researchers revealed that 23 men aged 40-75 years, who were diagnosed with an increased risk of developing prostate cancer, were admitted into this prospective clinical trial to determine the safety and tolerability of Zyflamend when administered orally for 18-months, either alone or along with various dietary supplements.
“Since we know that men with HGPIN have an increased risk for developing prostate cancer, new strategies formulated to decrease cancer risk, prevent or delay surgery, and improve quality of life, will be greatly beneficial for these men,” said senior author of the study Dr. Aaron E. Katz, an associate professor of Urology at Columbia University College of Physicians and Surgeons.
The researchers say that basic science studies have suggested that Zyflamend may have an anti-inflammatory mechanism of action, and the agent has been found to be effective in decreasing the proliferation of prostate cancer in cell culture.
“Our results confirm that Zyflamend, in a dose of three times daily for up to 18-months, was well tolerated,” said Dr. Jillian L. Capodice, director of the Acupuncture Research and Integrative Clinical Service of the Department of Urology’s Center for Holistic Urology, at Columbia University College of Physicians and Surgeons. (ANI)